Evidence map›Paper›PMID 39839139›Full record

ArticleFrontiers in psychiatry2024

Applied pharmacogenetics to predict response to treatment of first psychotic episode: study protocol.

Sergi Mas, Laura Julià, Manuel J Cuesta, Benedicto Crespo-Facorro, Javier Vázquez-Bourgon, Carlos Spuch, Ana Gonzalez-Pinto, Angela Ibañez, Judith Usall, Cristina Romero-López-Alberca and 3 more

Abstract read
In one paragraph

Article in Frontiers in psychiatry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Precision medicine in mental health: applications, challenges, and recommendations.European psychiatry : the journal of the Association of European Psychiatrists · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Sergi MasDepartment of Clinical Foundations, Pharmacology Unit, University of Barcelona, Barcelona, Spain.
Laura JuliàInstitut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPs), Barcelona, Spain.
Manuel J CuestaCentro de Investigación Biomédica en Red en Salud Mental (CIBERSAM), Madrid, Spain.
Benedicto Crespo-FacorroCentro de Investigación Biomédica en Red en Salud Mental (CIBERSAM), Madrid, Spain.
Javier Vázquez-BourgonCentro de Investigación Biomédica en Red en Salud Mental (CIBERSAM), Madrid, Spain.
Carlos SpuchCentro de Investigación Biomédica en Red en Salud Mental (CIBERSAM), Madrid, Spain.
Ana Gonzalez-PintoCentro de Investigación Biomédica en Red en Salud Mental (CIBERSAM), Madrid, Spain.
Angela IbañezCentro de Investigación Biomédica en Red en Salud Mental (CIBERSAM), Madrid, Spain.
Judith UsallInstitut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Barcelona, Spain.
Cristina Romero-López-AlbercaCentro de Investigación Biomédica en Red en Salud Mental (CIBERSAM), Madrid, Spain.
Ana CatalanCentro de Investigación Biomédica en Red en Salud Mental (CIBERSAM), Madrid, Spain.
Anna ManéCentro de Investigación Biomédica en Red en Salud Mental (CIBERSAM), Madrid, Spain.
Miquel BernardoInstitut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPs), Barcelona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The application of personalized medicine in patients with first-episode psychosis (FEP) requires tools for classifying patients according to their response to treatment, considering both treatment efficacy and toxicity. However, several limitations have hindered its translation into clinical practice. Here, we describe the rationale, aims and methodology of

Indexed as

antipsychoticpersonalized medicinePharmacogeneticspredictionpsychosis

Identifiers

PMID39839139
PMCPMC11747510

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.